SGLT-2 as a potential target in pancreatic cancer: the preliminary clue from The Cancer Genome Atlas data.
SGLT-2作為胰臟癌潛在治療靶點：來自癌症基因組圖譜數據的初步線索。
J Gastrointest Oncol 2022-11-19
Glucagon-Like Peptide 1-Based Therapies and Risk of Pancreatic Cancer in Patients With Diabetes and Obesity.
糖尿病和肥胖患者中胰臟癌風險的胰高血糖素樣肽1基礎治療。
Pancreas 2023-05-01
Association between sodium-glucose cotransporter 2 inhibitors and pancreatic cancer in the Japanese working-age population.
日本工作年齡人口中鈉葡萄糖共同轉運蛋白2抑制劑與胰臟癌之間的關聯。
Int J Clin Pharmacol Ther 2023-10-23
Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes.
二型糖尿病患者中胰臟癌風險與葡萄糖樣肽-1受體激動劑的關聯。
JAMA Netw Open 2024-01-08
Role of SGLT2 Inhibitors, DPP-4 Inhibitors, and Metformin in Pancreatic Cancer Prevention.
SGLT2抑制劑、DPP-4抑制劑和二甲双胍在胰臟癌預防中的作用。
Cancers (Basel) 2024-04-25
Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes.
GLP-1 受體激動劑與2型糖尿病患者肝細胞癌發生率及肝功能失調的關聯。
Gastroenterology 2024-05-20
Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication.
非酒精性脂肪肝病與胰臟癌之間的關聯：流行病學、機制和抗糖尿病藥物。
Hepatol Res 2024-06-17
Pancreatitis and Pancreatic Cancer Risk Among Patients With Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors: An Updated Meta-Analysis of Randomized Controlled Trials.
接受二肽基肽酶 4 抑制劑的 2 型糖尿病患者中胰臟炎與胰臟癌風險：隨機對照試驗的更新型統合分析。
Clin Ther 2024-07-31
Risk of Esophageal and Gastric Cancer in Patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis.
接受胰高血糖素樣肽-1 受體激動劑 (GLP-1 RAs) 的第二型糖尿病患者食道和胃癌風險：一項全國性分析。
Cancers (Basel) 2024-09-28
GLP-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data.
GLP-1 受體激動劑與胰臟癌風險：使用真實世界數據的目標試驗模擬。
J Natl Cancer Inst 2024-10-17